Prellis Biologics appoints new CEO and raises $35 million Bioprinting
Prellis Biologics, a biotherapeutics company utilizing its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro, has appointed Michael Nohaile, PhD as its new CEO, and has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures, and Lucas Venture Group. Dr. Michael Nohaile joins the company from Generate Biomedicines and succeeds Prellis Biologics founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat.